Epidermal growth factor receptor: Is a novel therapeutic target for pancreatic cancer?

Animesh Dhar; Smita Mehta; Snigdha Banerjee; Kakali Dhar; Gopal Dhar; Krishanu Sengupta; Gibanananda Ray; Sushanta K. Banerjee; Donald R. Campbell

doi:10.2741/1659

Epidermal growth factor receptor: Is a novel therapeutic target for pancreatic cancer?

Animesh Dhar, Smita Mehta, Snigdha Banerjee, Kakali Dhar, Gopal Dhar, Krishanu Sengupta, Gibanananda Ray, Sushanta K. Banerjee, Donald R. Campbell

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

9 Citas (Scopus)

Resumen

Expression of epidermal growth factor receptors (EGFR) is exaggerated in pancreatic adenocarcinoma and activation of EGFR appears to have an important role in the growth and differentiation of this and in other tumors. Therefore, blockade or inactivation of EGFR by monoclonal antibodies or by tyrosine kinase inhibitors has significant potential as an effective anti-cancer therapy. One of the very recent significant developments in the field of molecular biology involves the use of antisense of EGFR or EGFR gene silencing in pancreatic cancer cells as a potential targeted therapy for patients with pancreatic adenocarcinoma.

Idioma original	English
Páginas (desde-hasta)	1763-1767
Número de páginas	5
Publicación	Frontiers in Bioscience
Volumen	10
N.º	2
DOI	https://doi.org/10.2741/1659
Estado	Published - 2005
Publicado de forma externa	Sí

ASJC Scopus Subject Areas

General Biochemistry,Genetics and Molecular Biology
General Immunology and Microbiology

PubMed: MeSH publication types

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Review

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.2741/1659

Otros archivos y enlaces

Citar esto

@article{2410d9b67bbc49d8aab404ff268b5659,

title = "Epidermal growth factor receptor: Is a novel therapeutic target for pancreatic cancer?",

abstract = "Expression of epidermal growth factor receptors (EGFR) is exaggerated in pancreatic adenocarcinoma and activation of EGFR appears to have an important role in the growth and differentiation of this and in other tumors. Therefore, blockade or inactivation of EGFR by monoclonal antibodies or by tyrosine kinase inhibitors has significant potential as an effective anti-cancer therapy. One of the very recent significant developments in the field of molecular biology involves the use of antisense of EGFR or EGFR gene silencing in pancreatic cancer cells as a potential targeted therapy for patients with pancreatic adenocarcinoma.",

author = "Animesh Dhar and Smita Mehta and Snigdha Banerjee and Kakali Dhar and Gopal Dhar and Krishanu Sengupta and Gibanananda Ray and Banerjee, {Sushanta K.} and Campbell, {Donald R.}",

year = "2005",

doi = "10.2741/1659",

language = "English",

volume = "10",

pages = "1763--1767",

journal = "Frontiers in Bioscience",

issn = "2768-6701",

publisher = "Frontiers in Bioscience",

number = "2",

}

TY - JOUR

T1 - Epidermal growth factor receptor

T2 - Is a novel therapeutic target for pancreatic cancer?

AU - Dhar, Animesh

AU - Mehta, Smita

AU - Banerjee, Snigdha

AU - Dhar, Kakali

AU - Dhar, Gopal

AU - Sengupta, Krishanu

AU - Ray, Gibanananda

AU - Banerjee, Sushanta K.

AU - Campbell, Donald R.

PY - 2005

Y1 - 2005

N2 - Expression of epidermal growth factor receptors (EGFR) is exaggerated in pancreatic adenocarcinoma and activation of EGFR appears to have an important role in the growth and differentiation of this and in other tumors. Therefore, blockade or inactivation of EGFR by monoclonal antibodies or by tyrosine kinase inhibitors has significant potential as an effective anti-cancer therapy. One of the very recent significant developments in the field of molecular biology involves the use of antisense of EGFR or EGFR gene silencing in pancreatic cancer cells as a potential targeted therapy for patients with pancreatic adenocarcinoma.

AB - Expression of epidermal growth factor receptors (EGFR) is exaggerated in pancreatic adenocarcinoma and activation of EGFR appears to have an important role in the growth and differentiation of this and in other tumors. Therefore, blockade or inactivation of EGFR by monoclonal antibodies or by tyrosine kinase inhibitors has significant potential as an effective anti-cancer therapy. One of the very recent significant developments in the field of molecular biology involves the use of antisense of EGFR or EGFR gene silencing in pancreatic cancer cells as a potential targeted therapy for patients with pancreatic adenocarcinoma.

UR - http://www.scopus.com/inward/record.url?scp=17244375568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17244375568&partnerID=8YFLogxK

U2 - 10.2741/1659

DO - 10.2741/1659

M3 - Article

C2 - 15769665

AN - SCOPUS:17244375568

SN - 2768-6701

VL - 10

SP - 1763

EP - 1767

JO - Frontiers in Bioscience

JF - Frontiers in Bioscience

IS - 2

ER -

Epidermal growth factor receptor: Is a novel therapeutic target for pancreatic cancer?

Resumen

ASJC Scopus Subject Areas

PubMed: MeSH publication types

ODS de las Naciones Unidas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto